Vir Biotech Shares Rise on Positive Data for Cancer Treatments
Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage biopharmaceutical company said VIR-5818 targets HER2-expressing solid tumors,
The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by ...
The industry continues to face financial and regulatory headwinds, including high interest rates and uncertainty about ...
Press Trust of India on MSN48m
'Milestone In Biotechnology Research': PM Modi Unveils Genome Sequencing Data Of 10,000 IndiansPM Modi said more than 20 renowned research institutions like IITs, Council of Scientific and Industrial Research (CSIR), and ...
Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its ...
JPMorgan analyst Eric Joseph raised the firm’s price target on Vir Biotechnology (VIR) to $14 from $10 and keeps a Neutral rating on the shares.
Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...
Upstream's breeding technologies, which protect plants from yield-threatening diseases, have already delivered strong results ...
Prime Minister Narendra Modi said on Thursday that the combination of biotechnology and biomass is an important part of the ...
Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target ...
Nvidia shares rise after falling sharply in the previous session, Palantir stock extends declines, and quantum-computing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback